Worldwide there have been over 760 million confirmed coronavirus disease 2019 (COVID-
19) cases, and over 13 billion COVID-19 vaccine doses have been administered as of April …

Since COVID‐19 took a strong hold around the globe causing considerable morbidity and
mortality, a lot of effort was dedicated to manufacturing effective vaccines against SARS …

Vaccine-induced immune thrombotic thrombocytopaenia (VITT) is a rare adverse effect of
COVID-19 adenoviral vector vaccines,–. VITT resembles heparin-induced …

Background and purpose Population‐based studies suggest that severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2) vaccines may trigger immune‐mediated thrombotic …

Background Heterologous COVID-19 vaccination regimens combining vector-and mRNA-
based vaccines are already administered, but data on solicited adverse reactions …

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare yet serious adverse
effect of the adenoviral vector vaccines ChAdOx1 nCoV-19 (AstraZeneca) and Ad26. COV2 …

Introduction This study aims to provide a risk assessment of the adverse reactions related to
the COVID-19 vaccines manufactured by AstraZeneca, Janssen, Moderna, and Pfizer …

The current challenge worldwide is the administration of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) vaccine. Considering that the COVID-19 vaccination …

Background The rapid development of COVID-19 vaccines, combined with a high number of
adverse event reports, have led to concerns over possible mechanisms of injury including …

Thrombosis that occurs in coronavirus disease 19 (COVID-19) is a serious complication and
a critical aspect of pathogenesis in the disease progression. Although thrombocytopenia is …